GO:1905090 negative regulation of type 2 mitophagy

GO:1905090, negative regulation of type 2 mitophagy, defines any process that stops, prevents, or reduces the frequency, rate, or extent of type 2 mitophagy, the selective autophagic removal of mitochondria that depends on PRKN/Parkin-mediated stimulation following mitochondrial depolarization. Type 2 mitophagy is a cornerstone of mitochondrial quality control, and its negative regulation is critical for preserving mitochondrial mass when degradation would be detrimental, or conversely for allowing damaged mitochondria to persist in pathological states. Understanding this GO term is therefore central to dissecting how cells balance mitochondrial renewal and destruction under stress. Researchers have shown that hypoxia-induced depalmitoylation of GPCPD1 triggers mitophagy via PRKN-mediated ubiquitination of VDAC1, providing a direct mechanistic entry point into the regulation of type 2 mitophagy. Similarly, MANF facilitates breast cancer cell survival under glucose starvation by regulating PRKN-mediated mitophagy, illustrating how negative regulation of this process can support tumor adaptation. Viral pathogens can also hijack the machinery: classical swine fever virus recruits ESCRT-III and VPS4A to promote phagophore closure and accelerate mitophagy, a process whose negative regulation would oppose viral exploitation. In diabetes-related atrial remodeling, the LRRc17-RANKL pathway regulates mitophagy and contributes to pathology, highlighting the physiological importance of tuning type 2 mitophagy. NIPA2 modulates mitophagy in osteoblasts in type 2 diabetes osteoporosis, further linking this process to metabolic bone disease. PPP2/PP2A-mediated dephosphorylation of LC3B links PINK1-PRKN-mediated mitophagy to SCA12 pathogenesis, showing that phosphatases can act as negative regulators of the pathway. PTPN2 inhibition disrupts mitochondrial renewal and blocks TFRC-mediated mitophagy in ALK-positive anaplastic large cell lymphoma, underscoring therapeutic opportunities in cancer. Finally, cell type-specific mTOR-dependent distortion of autophagy pathways in lupus nephritis demonstrates that negative regulation of mitophagy is context-dependent and disease-relevant. This article synthesizes the authoritative QuickGO definition with these verified findings to provide a research-grade overview of GO:1905090, its mechanisms, key genes, disease links, and the CRISPR-based methods used to study it.

According to the Gene Ontology, GO:1905090 (negative regulation of type 2 mitophagy) is any biological process that stops, prevents, or reduces the frequency, rate, or extent of type 2 mitophagy. Type 2 mitophagy is the PRKN/Parkin-mediated autophagic clearance of mitochondria in response to mitochondrial depolarization. The term is synonymous with negative regulation of Park2-mediated stimulation of mitophagy in response to mitochondrial depolarization, negative regulation of parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization, and negative regulation of PRKN-mediated stimulation of mitophagy in response to mitochondrial depolarization. In practice, this means any molecular event that dampens the PINK1-PRKN ubiquitination cascade, impairs autophagosome formation around damaged mitochondria, or enhances mitochondrial retention can be classified under this term.

Negative regulation of type 2 mitophagy is important because it determines whether cells retain or eliminate damaged mitochondria, a decision that influences cell survival, metabolic fitness, and disease progression. In cancer, upregulation of negative regulators can allow tumor cells to survive glucose starvation by limiting excessive mitochondrial clearance. In diabetes, altered negative regulation contributes to atrial remodeling and osteoblast dysfunction. In neurodegeneration, phosphatase-mediated dephosphorylation of LC3B links negative regulation of mitophagy to SCA12 pathogenesis. Thus, understanding GO:1905090 provides mechanistic insight into a wide range of human pathologies and identifies candidate therapeutic targets.

The following genes and proteins have been experimentally linked to the regulation of type 2 mitophagy, including negative regulation, based on the verified PubMed literature.

Negative regulation of type 2 mitophagy is controlled at multiple levels. Upstream, PINK1 stabilization and PRKN recruitment are the primary triggers, and any process that reduces their activity or abundance acts as negative regulation. Post-translationally, deubiquitination of VDAC1 and other outer-membrane proteins directly opposes PRKN-mediated ubiquitination. Phosphatase complexes such as PPP2/PP2A dephosphorylate LC3B, dampening autophagosome formation and linking this regulation to SCA12 pathogenesis. Metabolic signaling through mTOR can distort autophagy pathways in a cell type-specific manner, as shown in lupus nephritis. Extracellular cues such as LRRc17-RANKL in diabetes and NIPA2 in osteoporosis further modulate the process. Viral proteins can hijack ESCRT-III and VPS4A to promote phagophore closure, and negative regulation would oppose this acceleration. Finally, PTPN2 inhibition disrupts mitochondrial renewal and blocks TFRC-mediated mitophagy in ALK-positive lymphoma, highlighting phosphatase-dependent control.

MANF facilitates breast cancer cell survival under glucose-starvation conditions via PRKN-mediated mitophagy regulation, indicating that negative regulation of type 2 mitophagy can support tumor adaptation to metabolic stress. In ALK-positive anaplastic large cell lymphoma, PTPN2 inhibition disrupts mitochondrial renewal and blocks TFRC-mediated mitophagy, suggesting that targeting negative regulators can exert anti-tumor activities. These findings position GO:1905090 as a potential therapeutic axis in oncology.

The LRRc17-RANKL pathway regulates mitophagy and contributes to atrial remodeling in diabetes, linking negative regulation of type 2 mitophagy to cardiac pathology. NIPA2 regulates osteoblast function by modulating mitophagy in type 2 diabetes osteoporosis, demonstrating a role in bone metabolism. These studies indicate that dysregulated negative regulation of mitophagy contributes to diabetic complications in multiple tissues.

PPP2/PP2A-mediated dephosphorylation of LC3B links PINK1-PRKN/Parkin-mediated mitophagy to SCA12 pathogenesis, providing a direct molecular connection between negative regulation of type 2 mitophagy and neurodegenerative disease. This suggests that modulating phosphatase activity could alter disease progression.

Cell type-specific mTOR-dependent distortion of autophagy pathways in lupus nephritis highlights how negative regulation of mitophagy can be rewired in autoimmune disease. Classical swine fever virus hijacks ESCRT-III and VPS4A to promote phagophore closure for accelerating mitophagy, indicating that viral pathogens can exploit or oppose negative regulation for their benefit.

Mitophagy flux is commonly measured using mt-Keima or mito-QC reporters that distinguish acidic autolysosomes from neutral mitochondria. These assays can quantify the rate of type 2 mitophagy and its negative regulation by candidate genes. In PRKN knockout backgrounds, rescue with wild-type or mutant PRKN can establish causality.

Immunoprecipitation of VDAC1 followed by ubiquitin immunoblotting can detect PRKN-mediated ubiquitination and its reversal by deubiquitinases. This method is essential for studying negative regulation at the level of ubiquitin editing. Mass spectrometry-based ubiquitin remnant profiling can identify site-specific changes.

Phos-tag gels and phospho-specific antibodies against LC3B can monitor PPP2/PP2A-mediated dephosphorylation. In vitro phosphatase assays using recombinant PPP2/PP2A and LC3B substrates can confirm direct regulation. These methods are critical for linking phosphatases to negative regulation of type 2 mitophagy.

Transmission electron microscopy can visualize autophagosomes containing mitochondria, providing ultrastructural evidence of mitophagy. Live-cell imaging of ESCRT-III or VPS4A tagged with fluorescent proteins can reveal phagophore closure dynamics. Correlative light and electron microscopy can bridge dynamic and structural data.

Researchers studying negative regulation of type 2 mitophagy-related genes often need to determine whether a candidate gene is causally involved in suppressing PRKN-dependent mitochondrial clearance, and CRISPR-based models provide the most direct way to establish that causality.

GO:1905090 negative regulation of type 2 mitophagy is a critical biological process that fine-tunes the PRKN/Parkin-dependent clearance of damaged mitochondria. The verified literature highlights diverse mechanisms, from GPCPD1 depalmitoylation and MANF signaling to ESCRT-III/VPS4A-mediated phagophore closure, PPP2/PP2A dephosphorylation of LC3B, and PTPN2-dependent control in lymphoma. These findings link negative regulation of type 2 mitophagy to cancer, diabetes, neurodegeneration, and autoimmune disease, making it a rich area for therapeutic targeting. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with mitophagy flux assays and bioinformatics, provide the tools needed to dissect this process and identify new drug targets.